Leerink

Despite a strong quarter, analysts see a difficult road ahead for Eli Lilly And Co (NYSE: LLY). “Even though Eli Lilly's launch execution has been outstanding," Leerink Managing Director Seamus Fernandez said, "the ways for LLY investors to win in our view appear limited when...

Leerink said in a note on Thursday it remains incrementally more cautious on the shares of Walgreens Boots Alliance Inc (NASDAQ: WBA) following the release of its quarterly results and after analyzing the new Rite Aid Corporation (NYSE: RAD) deal. Following a year-and-a-half dilly-dallying since...

Leerink raised its price target for Intuitive Surgical, Inc. (NASDAQ: ISRG), following a thorough model review, which increased the firm's conviction on the company. The revised price target represents a 17-percent upside from current levels. An Aggressive View Analysts Richard Newitter and...

After a nearly 60-percent return since the start of 2017, analysts at Leerink see further upside in shares of Align Technology, Inc. (NASDAQ: ALGN), a marketer and seller of digital services used in dentistry, orthodontics and dental records storage. Leerink's Richard Newitter maintains a Buy...

Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces. Clovis' conference calls came after the...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug. The company announced after Tuesday's close that Ingrezza didn't show a statistically significant difference on...

Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New Management As A Catalyst For Growth Leerink analyst Joseph Schwartz noted several opportunities could create a significant amount of shareholder value, including the...

Amazon.com, Inc. (NASDAQ: AMZN) has become known as the everything store. That's why it's no surprise recent reports have stated the company is interested to get into the pharmacy space. The e-commerce giant is reportedly hiring a business manager to figure out how it can possibly break...

Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks it will require a sizeable commercial effort to capture share in a market that has plateaued...

Express Scripts Holding Company (NASDAQ: ESRX) shares are bouncing back by 2.9 percent Wednesday after plummeting 10.7 percent Tuesday on news it is likely losing its largest customer, Anthem Inc (NYSE: ANTM). On Monday after the market close, Express issued a press release suggesting Anthem would...

Express Scripts Holding Company (NASDAQ: ESRX)'s earnings report was dominated by a concerning disclosure that it expects lose its largest customer, Anthem Inc (NYSE: ANTM). Anthem alleged that it is being overcharged by billions of dollars and is not expected to renew the contract, which expires...

Leerink said in a note Wednesday that Intuitive Surgical, Inc.'s (NASDAQ: ISRG) first quarter results give it even higher confidence in procedure growth trends. Leerink reiterated its Outperform rating and lifted its price target from $840 to $850, citing higher cash per share assumption....

Leerink sees the odds of the Walgreens Boots Alliance Inc (NASDAQ: WBA)-Rite Aid Corporation (NYSE: RAD) deal going through as 50/50. Walgreens negotiated a revised agreement on January 30 to acquire Rite Aid for $6.50 to $7 per share, depending on the number of Rite Aid store divestitures. The...

Last week, Fresenius Kabi, a subsidiary of Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) said it was looking into the possibility of acquiring Akorn, Inc. (NASDAQ: AKRX). Since the announcement, shares of the latter have spiked more than 30 percent, currently trading close to $32.75. In a...